Tumor Electric Fields Treatment System for Glioblastoma
This early phase I trial will investigate the safety and feasibility of applying the Tumor Electric Fields Treatment System to subjects with recurrent glioblastoma.
Glioblastoma
DEVICE: Tumor Electric Fields Treatment System
The treatment-related adverse events, Number of patients who experienced a treatment-related adverse event., 12 months|Time to Progression, Time to progression of patients with recurrent glioblastoma., 12 months|Overall Survival Rate, Number of patients alive at 12 months., 12 months
Subjects who have previously completed radiotherapy and at least two cycles of chemotherapy with imaging or pathological evidence of tumor recurrence will receive Tumor Electric Fields Treatment System. The main objective is to evaluate the safety of applying the Tumor Electric Fields Treatment System to subjects with recurrent GBM.